Implications of ABC transporters on the disposition of typical veterinary medicinal products

European Journal of Pharmacology

Volumn 585, Issue 2-3, 2008, Pages 510-519

  Schrickx, Jan A ^a   Fink Gremmels, Johanna ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

ABC; Drug; Milk; Species; Transport; Veterinary

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CIMETIDINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DAUNORUBICIN; DIGOXIN; DOXORUBICIN; ENROFLOXACIN; IVERMECTIN; KETOCONAZOLE; LOPERAMIDE; MACROLIDE; MILBEMYCIN; MOXIDECTIN; MULTIDRUG RESISTANCE PROTEIN 1; OXYTETRACYCLINE; PHENOBARBITAL; PROTEIN ABCC2; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RHODAMINE 123; UNINDEXED DRUG; VERAPAMIL; VETERINARY DRUG; VINBLASTINE; VINCRISTINE;

BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; DOG DISEASE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DISCRIMINATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; GENE FUNCTION; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; INTESTINAL ABSORPTION; MILK; MUTATION; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; VETERINARY DRUGS;

EID: 43049167381     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.03.014     Document Type: Review

References (168)

1. Adachi Y., Suzuki H., Schinkel A.H., and Sugiyama Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol. Pharmacol. 67 (2005) 923-928
2. Adachi Y., Suzuki H., and Sugiyama Y. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm. Res. 20 (2003) 1163-1169
3. Allen J.D., Brinkhuis R.F., Wijnholds J., and Schinkel A.H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 59 (1999) 4237-4241
4. Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., and Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58 (1998) 5337-5339
5. Alpert S., Mosher M., Shanske A., and Arias I.M. Multiplicity of hepatic excretory mechanisms for organic anions. J. Gen. Physiol. 53 (1969) 238-247
6. Alvarez, A.I., Perez, M., Prieto, J.G., Molina, A.J., Real, R., Merino, G., in press. Fluoroquinolone efflux mediated by ABC transporters. J. Pharm. Sci. doi:10.1002/jps.21233.
7. Anadon A., and Reeve-johnson L. Macrolide antibiotics, drug interactions and microsomal enzymes: implications for veterinary medicine. Res. Vet. Sci. 66 (1999) 197-203
8. Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov. Today 12 (2007) 838-843
9. Bachmeier C.J., Trickler W.J., and Miller D.W. Comparison of drug efflux transport kinetics in various blood-brain barrier models. Drug Metab. Dispos. 34 (2006) 998-1003
10. Baggetto L.G., Dong M., Bernaud J., Espinosa L., Rigal D., Bonvallet R., and Marthinet E. In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin. Biochem. Pharmacol. 56 (1998) 1219-1228
11. Baltes S., Gastens A.M., Fedrowitz M., Potschka H., Kaever V., and Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52 (2007) 333-346
12. Bauer B., Miller D.S., and Fricker G. Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharm. Res. 20 (2003) 1170-1176
13. Bishop B.F., Bruce C.I., Evans N.A., Goudie A.C., Gration K.A., Gibson S.P., Pacey M.S., Perry D.A., Walshe N.D., and Witty M.J. Selamectin: a novel broad-spectrum endectocide for dogs and cats. Vet. Parasitol. 91 (2000) 163-176
14. Boguski M.S., Lowe T.M., and Tolstoshev C.M. dbEST-database for "expressed sequence tags". Nat. Genet. 4 (1993) 332-333
15. Borst P., and Elferink R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71 (2002) 537-592
16. Brayden D.J., and Griffin J. Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. Vet. Res. Commun. 32 (2008) 93-106
17. Buchler M., Konig J., Brom M., Kartenbeck J., Spring H., Horie T., and Keppler D. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271 (1996) 15091-15098
18. Chandler B., Detsika M., Khoo S.H., Williams J., Back D.J., and Owen A. Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. J. Antimicrob. Chemother. 60 (2007) 685-689
19. Chandra P., and Brouwer K.L.R. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21 (2004) 719-735
20. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., and Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
21. Conrad S., Viertelhaus A., Orzechowski A., Hoogstraate J., Gjellan K., Schrenk D., and Kauffmann H.M. Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. Toxicology 156 (2001) 81-91
22. Cordon-Cardo C., O'Brien J., Boccia J., Casals D., Bertino J., and Melamed M. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38 (1990) 1277-1287
23. Culmsee K., Gruber A.D., von Samson-Himmelstjerna G., and Nolte I. Quantification of MDR-1 gene expression in canine tissues by real-time reverse transcription quantitative polymerase chain reaction. Res. Vet. Sci. 77 (2004) 223-229
24. Daigle J.C. More economical use of cyclosporine through combination drug therapy. J. Am. Anim. Hosp. Assoc. 38 (2002) 205-208
25. De Lannoy I.A., Koren G., Klein J., Charuk J., and Silverman M. Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am. J. Physiol. 263 (1992) F613-F622
26. Dhooge C., De Moerloose B., Laureys G., Kint J., Ferster A., De Bacquer D., Philippe J., and Benoit Y. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br. J. Haematol. 105 (1999) 676-683
27. Dietrich C.G., de Waart D.R., Ottenhoff R., Schoots I.G., and Elferink R.P.J.O. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol. Pharmacol. 59 (2001) 974-980
28. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., and Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U S A 95 (1998) 15665-15670
29. Drescher S., Glaeser H., Murdter T., Hitzl M., Eichelbaum M., and Fromm M.F. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther. 73 (2003) 223-231
30. Dupuy J., Lespine A., Sutra J.F., and Alvinerie M. The interaction between moxidectin and MDR transporters in primary cultures of rat hepatocytes. J. Vet. Pharmacol. Ther. 29 (2006) 107-111
31. Eberl S., Renner B., Neubert A., Reisig M., Bachmakov I., Konig J., Dorje F., Murdter T.E., Ackermann A., Dormann H., Gassmann K.G., Hahn E.G., Zierhut S., Brune K., and Fromm M.F. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46 (2007) 1039-1049
32. Edelmann H.M., Duchek P., Rosenthal F.E., Foger N., Glackin C., Kane S.E., and Kuchler K. Cmdr1, a chicken P-glycoprotein, confers multidrug resistance and interacts with estradiol. Biol. Chem. 380 (1999) 231-241
33. Eisenblatter T., and Galla H.J. A new multidrug resistance protein at the blood-brain barrier. Biochem. Biophys. Res. Commun. 293 (2002) 1273-1278
34. Enokizono J., Kusuhara H., and Sugiyama Y. Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases. Drug Metab. Dispos. 35 (2007) 922-928
35. Escudero E., Carceles C.M., Fernandez-varon E., Marin P., and Benchaoui H. Pharmacokinetics of danofloxacin 18% in lactating sheep and goats. J. Vet. Pharmacol. Ther. 30 (2007) 572-577
36. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U S A 84 (1987) 265-269
37. Friis C., and Nielsen J.P. Penetration of danofloxacin into the respiratory tract tissues and secretions in healthy and Actinobacillus pleuropneumoniae infected pigs. J. Vet. Pharm. Ther. 20 (1997) 87-109
38. Fromm M.F., Kim R.B., Stein C.M., Wilkinson G.R., and Roden D.M. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99 (1999) 552-557
39. Geyer J., Doring B., Godoy J.R., Leidolf R., Moritz A., and Petzinger E. Frequency of the nt230 (del4) MDR1 mutation in collies and related dog breeds in Germany. J. Vet. Pharmacol. Ther. 28 (2005) 545-551
40. Geyer J., Doring B., Godoy J.R., Moritz A., and Petzinger E. Development of a PCR-based diagnostic test detecting a nt230(del4) MDR1 mutation in dogs: verification in a moxidectin-sensitive Australian Shepherd. J. Vet. Pharmacol. Ther. 28 (2005) 95-99
41. Geyer J., Klintzsch S., Meerkamp K., Wohlke A., Distl O., Moritz A., and Petzinger E. Detection of the nt230(del4) MDR1 mutation in White Swiss Shepherd dogs: case reports of doramectin toxicosis, breed predisposition, and microsatellite analysis. J. Vet. Pharmacol. Ther. 30 (2007) 482-485
42. Gillet J.P., Efferth T., and Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 1775 (2007) 237-262
43. Ginn P.E. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet. Pathol. 33 (1996) 533-541
44. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., and Kroemer H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104 (1999) 147-153
45. Griffin J., Fletcher N., Clemence R., Blanchflower S., and Brayden D.J. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J. Vet. Pharmacol. Ther. 28 (2005) 257-265
46. Gros P., Croop J., Roninson I., Varshavsky A., and Housman D.E. Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells. Proc. Natl. Acad. Sci. U S A 83 (1986) 337-341
47. Handschin C., Podvinec M., and Meyer U.A. CXR, a chicken xenobiotic-sensing orphan nuclear receptor, is related to both mammalian pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Proc. Natl. Acad. Sci. U S A 97 (2000) 10769-10774
48. Haritova, A.M., 2006. PK-PD modeling of fluoroquinolones and ABC transporters in poultry, in: Veterinary Pharmacology, Pharmacy and Toxicology, Vol. Ph.D. (Utrecht University, Utrecht).
49. Hedman A., Angelin B., Arvidsson A., Beck O., Dahlqvist R., Nilsson B., Olsson M., and Schenck-Gustafsson K. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin. Pharmacol. Ther. 49 (1991) 256-262
50. Henik R.A., Kellum H.B., Bentjen S.A., and Mealey K.L. Digoxin and mexiletine sensitivity in a collie with the MDR1 mutation. J. Vet. Intern. Med. 20 (2006) 415-417
51. Hennessy M., Kelleher D., Spiers J.P., Barry M., Kavanagh P., Back D., Mulcahy F., and Feely J. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol. 53 (2002) 75-82
52. Herrstedt J., and Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin. Pharmacol. Toxicol. 101 (2007) 143-150
53. Herwaarden A.E.v., Wagenaar E., Karnekamp B., Merino G., Jonker J.W., and Schinkel A.H. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk 10.1093/carcin/bgi176. Carcinogenesis 27 (2006) 123-130
54. Hirano M., Maeda K., Matsushima S., Nozaki Y., Kusuhara H., and Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 68 (2005) 800-807 10.1124/mol.105.014019
55. Hiroyuki Kusuhara H.S., and Yuichi S. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci. 87 (1998) 1025-1040
56. Huls M., Brown C.D., Windass A.S., Sayer R., van den Heuvel J.J., Heemskerk S., Russel F.G., and Masereeuw R. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 73 (2008) 220-225
57. Igel S., Drescher S., Murdter T., Hofmann U., Heinkele G., Tegude H., Glaeser H., Brenner S.S., Somogyi A.A., Omari T., Schafer C., Eichelbaum M., and Fromm M.F. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin. Pharmacokinet. 46 (2007) 777-785
58. Imperiale F.A., Busetti M.R., Suarez V.H., and Lanusse C.E. Milk excretion of ivermectin and moxidectin in dairy sheep: assessment of drug residues during cheese elaboration and ripening period. J. Agric. Food Chem. 52 (2004) 6205-6211
59. Ishizuka H., Konno K., Shiina T., Naganuma H., Nishimura K., Ito K., Suzuki H., and Sugiyama Y. Species differences in the transport activity for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther. 290 (1999) 1324-1330
60. Jongsma A.P., Spengler B.A., Van der Bliek A.M., Borst P., and Biedler J.L. Chromosomal localization of three genes coamplified in the multidrug-resistant CHRC5 Chinese hamster ovary cell line. Cancer Res. 47 (1987) 2875-2878
61. Jonker J.W., Buitelaar M., Wagenaar E., Van Der Valk M.A., Scheffer G.L., Scheper R.J., Plosch T., Kuipers F., Elferink R.P., Rosing H., Beijnen J.H., and Schinkel A.H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U S A 99 (2002) 15649-15654
62. Jonker J.W., Merino G., Musters S., van Herwaarden A.E., Bolscher E., Wagenaar E., Mesman E., Dale T.C., and Schinkel A.H. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11 (2005) 127-129
63. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H.M., and Schinkel A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92 (2000) 1651-1656
64. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455 (1976) 152-162
65. Kaartinen L., Salonen M., Alli L., and Pyorala S. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. J. Vet. Pharmacol. Ther. 18 (1995) 357-362
66. Kageyama M., Fukushima K., Togawa T., Fujimoto K., Taki M., Nishimura A., Ito Y., Sugioka N., Shibata N., and Takada K. Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol. Pharm. Bull. 29 (2006) 779-784
67. Katoh M., Suzuyama N., Takeuchi T., Yoshitomi S., Asahi S., and Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J. Pharm. Sci. 95 (2006) 2673-2683
68. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 234 (2006) 4-33
69. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., and Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
70. Kitamura T., Alroy J., Gatmaitan Z., Inoue M., Mikami T., Jansen P., and Arias I.M. Defective biliary excretion of epinephrine metabolites in mutant (TR-) rats: relation to the pathogenesis of black liver in the Dubin-Johnson syndrome and Corriedale sheep with an analogous excretory defect. Hepatology 15 (1992) 1154-1159
71. Konig J., Nies A.T., Cui Y., Leier I., and Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461 (1999) 377-394
72. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., Baas F., and Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57 (1997) 3537-3547
73. Kruijtzer C.M., Beijnen J.H., and Schellens J.H. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7 (2002) 516-530
74. Laffont C.M., Toutain P.-L., Alvinerie M., and Bousquet-Melou A. Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab. Dispos. 30 (2002) 626-630
75. Lagas J.S., Sparidans R.W., van Waterschoot R.A., Wagenaar E., Beijnen J.H., and Schinkel A.H. P-glycoprotein limits oral availability, brain penetration and toxicity of an anionic drug, the antibiotic salinomycin. Antimicrob. Agents. Chemother. 52 (2008) 1034-1039
76. Lallemand E., Lespine A., Alvinerie M., Bousquet-Melou A., and Toutain P.L. Estimation of absolute oral bioavailability of moxidectin in dogs using a semi-simultaneous method: influence of lipid co-administration. J. Vet. Pharmacol. Ther. 30 (2007) 375-380
77. Lamba J.K., Lamba V., Yasuda K., Lin Y.S., Assem M., Thompson E., Strom S., and Schuetz E. Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J. Pharmacol. Exp. Ther. 311 (2004) 811-821
78. Langmann T., Mauerer R., Zahn A., Moehle C., Probst M., Stremmel W., and Schmitz G. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin. Chem. 49 (2003) 230-238
79. Lee J.J., Hughes C.S., Fine R.L., and Page R.L. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 77 (1996) 1892-1898
80. Li L., Xu J., Min T., and Huang W. Reversal of MDR1 gene-dependent multidrug resistance using low concentration of endonuclease-prepared small interference RNA. Eur. J. Pharmacol. 536 (2006) 93-97
81. Lindecrona R.H., Friis C., and Nielsen J.P. Pharmacokinetics and penetration of danofloxacin into the gastrointestinal tract in healthy and in Salmonella typhimurium infected pigs. Res. Vet. Sci. 68 (2000) 211-216
82. Liu L., Cui Y., Chung A.Y., Shitara Y., Sugiyama Y., Keppler D., and Pang K.S. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol. Exp. Ther. 318 (2006) 395-402
83. Ma L., Pratt S.E., Cao J., Dantzig A.H., Moore R.E., and Slapak C.A. Identification and characterization of the canine multidrug resistance-associated protein. Mol. Cancer Ther. 1 (2002) 1335-1342
84. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., and Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61 (2001) 3458-3464
85. Marathe P.H., and Rodrigues A.D. In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions. Curr. Drug Metab. 7 (2006) 687-704
86. Mayer R., Kartenbeck J., Buchler M., Jedlitschky G., Leier I., and Keppler D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J. Cell Biol. 131 (1995) 137-150
87. Mayer U., Wagenaar E., Beijnen J.H., Smit J.W., Meijer D.K., van Asperen J., Borst P., and Schinkel A.H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol. 119 (1996) 1038-1044
88. McEntee M., Silverman J.A., Rassnick K., Zgola M., Chan A.O., Tau P.T., and Page R.L. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet. Comp. Oncol. 1 (2003) 105-112
89. McEntee M.C., Rassnick K.M., Bailey D.B., Balkman C.E., Flanagan J.L., Beaulieu B.B., Zgola M.M., Lewis L.D., and Page R.L. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing cats. J. Vet. Intern. Med. 20 (2006) 1370-1375
90. McEntee M.C., Rassnick K.M., Lewis L.D., Zgola M.M., Beaulieu B.B., Balkman C.E., and Page R.L. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. Am. J. Vet. Res. 67 (2006) 1057-1062
91. McKellar Q.A., Gibson I.F., and McCormack R.Z. Pharmacokinetics and tissue disposition of danofloxacin in sheep. Biopharm. Drug Dispos. 19 (1998) 123-129
92. Mealey K.L. A new tool that detects ivermectin and other drug sensitivities in dogs. Vet. Med. 99 (2004) 419-426
93. Mealey K.L. Pharmacogenetics. Vet. Clin. North Am. Small Anim. Pract. 36 (2006) 961-973 v
94. Mealey K.L., Bentjen S.A., Gay J.M., and Cantor G.H. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11 (2001) 727-733
95. Mealey K.L., Northrup N.C., and Bentjen S.A. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J. Am. Vet. Med. Assoc. 223 (2003) 1453-1455 1434
96. Merino G., Alvarez A.I., Pulido M.M., Molina A.J., Schinkel A.H., and Prieto J.G. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab. Dispos. 34 (2006) 690-695
97. Merino G., Jonker J.W., Wagenaar E., van Herwaarden A.E., and Schinkel A.H. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol. Pharmacol. 67 (2005) 1758-1764
98. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., and Bates S.E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59 (1999) 8-13
99. Miyoshi M., Nadai M., Nitta A., Ueyama J., Shimizu A., Takagi K., Nabeshima T., Takagi K., Saito K., and Hasegawa T. Role of tumor necrosis factor-alpha in down-regulation of hepatic cytochrome P450 and P-glycoprotein by endotoxin. Eur. J. Pharmacol. 507 (2005) 229-237
100. Mizuno N., Suzuki M., Kusuhara H., Suzuki H., Takeuchi K., Niwa T., Jonker J.W., and Sugiyama Y. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (e3040) sulfate in Breast Cancer Resistance Protein (BCRP1/ABCG2) knockout mice. Drug Metab. Dispos. 32 (2004) 898-901
101. Morris M.E., and Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci. 78 (2006) 2116-2130
102. Morschhauser F., Zinzani P.L., Burgess M., Sloots L., Bouafia F., and Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar·3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk. Lymphoma 48 (2007) 708-715
103. Neff M.W., Robertson K.R., Wong A.K., Safra N., Broman K.W., Slatkin M., Mealey K.L., and Pedersen N.C. Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc. Natl. Acad. Sci. U S A 101 (2004) 11725-11730
104. Ninomiya M., Ito K., and Horie T. Functional analysis of dog multidrug resistance-associated protein 2 (mrp2) in comparison with rat mrp2. Drug Metab. Dispos. 33 (2005) 225-232
105. Nishihara K., Hibino J., Kotaki H., Sawada Y., and Iga T. Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. Biopharm. Drug Dispos. 20 (1999) 145-149
106. Novotny M.J., Krautmann M.J., Ehrhart J.C., Godin C.S., Evans E.I., McCall J.W., Sun F., Rowan T.G., and Jernigan A.D. Safety of selamectin in dogs. Vet. Parasitol. 91 (2000) 377-391
107. Nunoya K., Grant C.E., Zhang D., Cole S.P.C., and Deeley R.G. Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab. Dispos. 31 (2003) 1016-1026
108. Okai Y., Nakamura N., Matsushiro H., Kato H., Setoguchi A., Yazawa M., Okuda M., Watari T., Hasegawa A., and Tsujimoto H. Molecular analysis of multidrug resistance in feline lymphoma cells. Am. J. Vet. Res. 61 (2000) 1122-1127
109. Oude Elferink R.P., Ottenhoff R., Liefting W.G., Schoemaker B., Groen A.K., and Jansen P.L. ATP-dependent efflux of GSSG and GS-conjugate from isolated rat hepatocytes. Am. J. Physiol. 258 (1990) G699-G706
110. Oude Elferink R.P.J., Meijer D.K.F., Kuipers F., Jansen P.L.M., Groen A.K., and Groothuis G.M.M. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta (BBA) - Rev. Biomembr. 1241 (1995) 215-268
111. Paul A.J., Hutchens D.E., Firkins L.D., and Borgstrom M. Dermal safety study with imidacloprid/moxidectin topical solution in the ivermectin-sensitive collie. Vet. Parasitol. 121 (2004) 285-291
112. Paulusma C.C., Bosma P.J., Zaman G.J., Bakker C.T., Otter M., Scheffer G.L., Scheper R.J., Borst P., and Oude Elferink R.P. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271 (1996) 1126-1128
113. Petterino C., Martini M., and Castagnaro M. Immunohistochemical detection of growth hormone (GH) in canine hepatoid gland tumors. J. Vet. Med. Sci. 66 (2004) 569-572
114. Pulido M.M., Molina A.J., Merino G., Mendoza G., Prieto J.G., and Alvarez A.I. Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J. Vet. Pharmacol. Ther. 29 (2006) 279-287
115. Rantala M., Kaartinen L., Valimaki E., Stryrman M., Hiekkaranta M., Niemi A., Saari L., and Pyorala S. Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. J. Vet. Pharmacol. Ther. 25 (2002) 251-258
116. Ratz V., Laczay P., Mora Z., Csiko G., Monostori K., Vereczkey L., Lehel J., and Semjen G. Recent studies on the effects of tiamulin and monensin on hepatic cytochrome P450 activities in chickens and turkeys. J. Vet. Pharmacol. Ther. 20 (1997) 415-418
117. Ravis W.R., Pedersoli W.M., and Turco J.D. Pharmacokinetics and interactions of digoxin with phenobarbital in dogs. Am. J. Vet. Res. 48 (1987) 1244-1249
118. Robieux I., Dorian P., Klein J., Chung D., Zborowska-Sluis D., Ogilvie R., and Koren G. The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. J. Clin. Pharmacol. 32 (1992) 338-343
119. Robson D. Review of the pharmacokinetics, interactions and adverse reactions of cyclosporine in people, dogs and cats. Vet. Rec. 152 (2003) 739-748
120. Rosati A., Maniori S., Decorti G., Candussio L., Giraldi T., and Bartoli F. Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev. Growth Differ. 45 (2003) 377-387
121. Funakoshi S., Murakami T., Yumoto R., Kiribayashi Y., and Takano M. Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and beta-methyldigoxin in rats. J. Pharm. Sci. 92 (2003) 1455-1463
122. Sartor L.L., Bentjen S.A., Trepanier L., and Mealey K.L. Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J. Vet. Intern. Med. 18 (2004) 117-118
123. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., and Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U S A 94 (1997) 4028-4033
124. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
125. Schrickx J., and Fink-Gremmels J. P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model. J. Vet. Pharmacol. Ther. 30 (2007) 25-31
126. Schrickx J.A., and Fink-Gremmels J. Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters. Br. J. Pharmacol. 150 (2007) 463-469
127. Schrickx, J.A., 2006. ABC-transporters in the pig. Ph.D. thesis Veterinary Pharmacology, Pharmacy and Toxicology (Utrecht University, Utrecht).
128. Sesink A.L.A., Arts I.C.W., de Boer V.C.J., Breedveld P., Schellens J.H.M., Hollman P.C.H., and Russel F.G.M. Breast Cancer Resistance Protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol. Pharmacol. 67 (2005) 1999-2006
129. Shem-Tov M., Rav-Hon O., Ziv G., Lavi E., Glickman A., and Saran A. Pharmacokinetics and penetration of danofloxacin from the blood into the milk of cows. J. Vet. Pharm. Ther. 21 (1998) 209-213
130. Shem-Tov M., Rav-Hon O., Ziv G., Lavi E., Glickman A., and Saran A. Pharmacokinetics and penetration of danofloxacin from the blood into the milk of cows. J. Vet. Pharmacol. Ther. 21 (1998) 209-213
131. Shimizu A., Miyoshi M., Sugie M., Ueyama J., Yamaguchi T., Sasaki T., Takagi K., Jin M., Miyamoto K., Tsuji A., and Hasegawa T. Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Eur. J. Pharmacol. 501 (2004) 151-159
132. Smit J.W., Schinkel A.H., Weert B., and Meijer D.K. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br. J. Pharmacol. 124 (1998) 416-424
133. Smith A.J., van Helvoort A., van Meer G., Szabo K., Welker E., Szakacs G., Varadi A., Sarkadi B., and Borst P. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem. 275 (2000) 23530-23539
134. Sorgel F., Naber K.G., Jaehde U., Reiter A., Seelmann R., and Sigl G. Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am. J. Med. 87 (1989) 62S-65S
135. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., and Van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U S A 94 (1997) 2031-2035
136. Steingold S.F., Sharp N.J., McGahan M.C., Hughes C.S., Dunn S.E., and Page R.L. Characterization of canine MDR1 mRNA: its abundance in drug resistant cell lines and in vivo. Anticancer. Res. 18 (1998) 393-400
137. Stride B.D., Grant C.E., Loe D.W., Hipfner D.R., Cole S.P.C., and Deeley R.G. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol. Pharmacol. 52 (1997) 344-353
138. Styczynski J., Wysocki M., Debski R., Czyzewski K., Kolodziej B., Rafinska B., Kubicka M., Koltan S., Koltan A., Pogorzala M., Kurylak A., Olszewska-Slonina D., Balwierz W., Juraszewska E., Wieczorek M., Olejnik I., Krawczuk-Rybak M., Kuzmicz M., Kowalczyk J., Stefaniak J., Badowska W., Sonta-Jakimczyk D., Szczepanski T., Matysiak M., Malinowska I., Stanczak E., Wachowiak J., Konatkowska B., Gil L., Balcerska A., and Maciejka-Kapuscinska L. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J. Cancer Res. Clin. Oncol. 133 (2007) 875-893
139. Suzuki M., Suzuki H., Sugimoto Y., and Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem. 278 (2003) 22644-22649
140. Suzuyama N., Katoh M., Takeuchi T., Yoshitomi S., Higuchi T., Asashi S., and Yokoi T. Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J. Pharm. Sci. 96 (2007) 1609-1618
141. Szakacs G., Annereau J.P., Lababidi S., Shankavaram U., Arciello A., Bussey K.J., Reinhold W., Guo Y., Kruh G.D., Reimers M., Weinstein J.N., and Gottesman M.M. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6 (2004) 129-137
142. Szucs G., Tamasi V., Laczay P., and Monostory K. Biochemical background of toxic interaction between tiamulin and monensin. Chem. Biol. Interact. 147 (2004) 151-161
143. Taguchi Y., Saeki K., and Komano T. Functional analysis of MRP1 cloned from bovine. FEBS Lett. 521 (2002) 211-213
144. Takeuchi T., Yoshitomi S., Higuchi T., Ikemoto K., Niwa S., Ebihara T., Katoh M., Yokoi T., and Asahi S. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm. Res. 23 (2006) 1460-1472
145. Tanaka Y., Slitt A.L., Leazer T.M., Maher J.M., and Klaassen C.D. Tissue
146. Tashbaeva R.E., Hwang D.N., Song G.S., Choi N.H., Lee J.H., Lyoo Y.S., Lee S.J., Jung D.I., Kim H.Y., and Sur J.H. Cellular characterization of multidrug resistance P-glycoprotein, alpha fetoprotein, and neovascular endothelium-associated antigens in canine hepatocellular carcinoma and cirrhotic liver. Vet. Pathol. 44 (2007) 600-606
147. Taub M.E., Podila L., Ely D., and Almeida I. Functional assessment of multiple p-glycoprotein (p-gp) probe substrates: influence of cell line and modulator concentration on p-gp activity. Drug Metab. Dispos. 33 (2005) 1679-1687
148. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U S A 84 (1987) 7735-7738
149. Tocco D.J., deLuna F.A., Duncan A.E., Vassil T.C., and Ulm E.H. The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab. Dispos. 10 (1982) 15-19
150. Tsunoda S., Okumura T., Ito T., Kondo K., Ortiz C., Tanaka E., Watanabe G., Itami A., Sakai Y., and Shimada Y. ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 71 (2006) 251-258
151. Tulpule A. Multidrug resistance in AIDS-related lymphoma. Curr. Opin. Oncol. 17 (2005) 466-468
152. Uhr M., Steckler T., Yassouridis A., and Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22 (2000) 380-387
153. van de Water F.M., Masereeuw R., and Russel F.G. Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug. Metab. Rev. 37 (2005) 443-471
154. Van der Bliek A.M., Van der Velde-Koerts T., Ling V., and Borst P. Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol. Cell Biol. 6 (1986) 1671-1678
155. van der Pol M.A., Broxterman H.J., Pater J.M., Feller N., van der Maas M., Weijers G.W., Scheffer G.L., Allen J.D., Scheper R.J., van Loevezijn A., Ossenkoppele G.J., and Schuurhuis G.J. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 88 (2003) 134-147
156. van Herwaarden A.E., Jonker J.W., Wagenaar E., Brinkhuis R.F., Schellens J.H., Beijnen J.H., and Schinkel A.H. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63 (2003) 6447-6452
157. van Herwaarden A.E., Wagenaar E., Karnekamp B., Merino G., Jonker J.W., and Schinkel A.H. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27 (2006) 123-130
158. van Kuijck M.A., Kool M., Merkx G.F., Geurts van Kessel A., Bindels R.J., Deen P.M., and Van Os C.H. Assignment of the canalicular multispecific organic anion transporter gene (CMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization. Cytogenet. Cel. Genet. 77 (1997) 285-287
159. van Montfoort J.E., Hagenbuch B., Groothuis G.M., Koepsell H., Meier P.J., and Meijer D.K. Drug uptake systems in liver and kidney. Curr. Drug. Metab. 4 (2003) 185-211
160. Verschraagen M., Koks C.H.W., Schellens J.H.M., and Beijnen J.H. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharm. Res. 40 (1999) 301-306
161. Wacher V.J., Wu C.Y., and Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13 (1995) 129-134
162. Wang H., Wu X., Hudkins K., Mikheev A., Zhang H., Gupta A., Unadkat J.D., and Mao Q. Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am. J. Physiol. Endocrinol. Metab. 291 (2006) E1295-E1304
163. Yamaguchi H., Yano I., Saito H., and Inui K.-i. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J. Pharmacol. Exp. Ther. 300 (2002) 1063-1069
164. Zaher H., Khan A.A., Palandra J., Brayman T.G., Yu L., and Ware J.A. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm. 3 (2006) 55-61
165. Zamek-Gliszczynski M.J., Hoffmaster K.A., Tian X., Zhao R., Polli J.W., Humphreys J.E., Webster L.O., Bridges A.S., Kalvass J.C., and Brouwer K.L. Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug. Metab. Dispos. 33 (2005) 1158-1165
166. Zamek-Gliszczynski M.J., Nezasa K., Tian X., Kalvass J.C., Patel N.J., Raub T.J., and Brouwer K.L. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol. Pharmacol. 70 (2006) 2127-2133
167. Zhou S., Lim L.Y., and Chowbay B. Herbal modulation of P-glycoprotein. Drug. Metab. Rev. 36 (2004) 57-104
168. Zimniak P. Dubin-Johnson and Rotor syndromes: molecular basis and pathogenesis. Semin. Liver Dis. 13 (1993) 248-260